...
首页> 外文期刊>Journal of Biomedical Science and Engineering >In vitro and in vivo cell tracking of chondrocytes of different origin by fluorescent PKH 26 and CMFDA
【24h】

In vitro and in vivo cell tracking of chondrocytes of different origin by fluorescent PKH 26 and CMFDA

机译:通过荧光PKH 26和CMFDA对不同来源的软骨细胞进行体外和体内细胞追踪

获取原文

摘要

Tissue engineering techniques for cartilage re-pair to heal defects in joint surfaces is a clinical practice. Harvested autologous chondrocytes are expanded in culture and delivered in a suitable carrier medium back into the patient>s joint de-fect. The defect is then subsequently filled by new cartilage. Whether the cells in the repair tissue originate from the engineered tissue of the host or are derived from the surrounding original cartilage remains a relevant question for the ap-plied therapy. To answer this several methods exist to track cells, such as transfection of cells with LacZ carrying viruses, radio labeling with 111 IN or 51 Cr or fluorescent labeling with FDA. However, these techniques have drawbacks such as they may influence cellular properties, are radioactive and or quickly lose their tracking ability. New fluorescent probes are easier to handle and do not to interfere with cells. PKH 26劌 is a relatively new cell-labeling agent, but few data exist on the application of this dye in chondrocytes in vitro and in vivo. 5-chloromethylfluorescein diacetate - CMFDA (¨cell tracker green〔) is an established fluores-cent probe for imaging the dynamic processes of cell proliferation in vitro and in vivo. Likewise, several studies exist on different cell types. However, little data are available for chondro-cytes. The first aim of the study was to evaluate qualitative differences in fluorescence pattern after labeling of articular, auricular and costal chondrocytes. Secondly, we evaluated the influ-ence of labeling with CMFDA on cellular adhe-sion properties. The third aim was to compare the duration of cell labeling of chondrocytes of different origin with established CMFDA as stan-dard and PKH 26潴 for 3 cell generations in vitro and 12 weeks in vivo. We show that chondro-cytes from different origin can be labeled effec-tively with both PKH 26潴 and CMFDA. The PKH 26潴 labeled articular chondrocytes maintained fluorescence longer than CMFDA in vitro and in vivo. A higher percentage of articular chondro-cytes remained stained at 63 days than auricular or costal chondrocytes.
机译:用于软骨修复以修复关节表面缺陷的组织工程技术是一种临床实践。收获的自体软骨细胞在培养中扩增,并在合适的载体培养基中输送回患者的关节缺损中。然后用新的软骨填充缺损。修复组织中的细胞是起源于宿主的工程组织还是源自周围的原始软骨,仍然是应用疗法的一个相关问题。为了回答这个问题,存在几种跟踪细胞的方法,例如用携带LacZ的病毒转染细胞,用111 IN或51 Cr进行放射性标记或用FDA进行荧光标记。然而,这些技术具有缺点,例如它们可能影响细胞特性,具有放射性和/或迅速失去其跟踪能力。新的荧光探针更易于操作,并且不会干扰细胞。 PKH 26是一种相对较新的细胞标记剂,但是关于这种染料在体外和体内在软骨细胞中的应用的数据很少。 5-氯甲基荧光素二乙酸酯-CMFDA(amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp; amp;#168;细胞跟踪仪green〔))是一种用于在体外和体内成像细胞增殖动态过程的荧光探针。同样,对不同细胞类型也进行了一些研究。但是,软骨细胞的数据很少。该研究的第一个目的是评估在标记关节,耳廓和肋软骨细胞后荧光模式的质量差异。其次,我们评估了CMFDA标记对细胞粘附特性的影响。第三个目标是比较已建立的CMFDA作为标准品和PKH 26 3对不同来源的软骨细胞进行细胞标记的持续时间,在体外和体内分别进行了3代细胞的研究。我们显示,不同来源的软骨细胞可以同时用PKH 26和CMFDA进行标记。在体外和体内,PKH 26 cho标记的关节软骨细胞比CMFDA保持更长的荧光。与耳廓或肋软骨细胞相比,在63天时仍有较高百分比的关节软骨细胞保持染色。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号